Anna Halpern, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Bayer
    Topic: 
    research contract
    Date added: 
    05/27/2022
    Relationship end date: 
    08/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Jazz pharmaceuticals
    Topic: 
    research contract
    Date added: 
    05/27/2022
    Relationship end date: 
    10/22/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Imago Biosciences
    Topic: 
    research contract
    Date added: 
    05/27/2022
    Relationship end date: 
    08/31/2026
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Gilead Sciences
    Topic: 
    research contract
    Date added: 
    05/27/2022
    Relationship end date: 
    12/31/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Karyopharm Therapeutics
    Topic: 
    research contract
    Date added: 
    05/27/2022
    Relationship end date: 
    10/31/2026
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Incytes Pharmaceuticals
    Topic: 
    research contract
    Date added: 
    05/27/2022
    Relationship end date: 
    12/31/2026
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Abbvie
    Topic: 
    consulting
    Date added: 
    05/27/2022
    Relationship end date: 
    06/01/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Notable Labs
    Topic: 
    consulting
    Date added: 
    05/27/2022
    Relationship end date: 
    04/06/2022
Return to BTF’s ASH Annual Meeting Review 2023 - Coeur d’Alene